Abstract: The present invention is directed towards a compacted powder shaped to comprise: a) a substantially annular girdle having opposing circumferential edges, the girdle having a diameter (x); and b) a dome protruding from each of the opposing circumferential edges of the girdle, wherein the height of each dome (hd) from the circumferential edge is, individually, about 0.18x to about 0.28x.

Abstract: The present invention relates to a neurotrophic factor carrier, particularly to a neurotrophic factor carrier wherein the neurotrophic factor is contained in a porous nerve conduit having micropores formed in microchannels, a method for preparing the same and a method for regenerating a nerve using the same, wherein the neurotrophic factor carrier prepared according to the present invention is applicable to in-vitro and in-vivo researches on nerves.

Abstract: Embodiments of the present invention pertain to antimicrobial glass compositions, glasses and articles. The articles include a glass, which may include a glass phase and a cuprite phase. In other embodiments, the glasses include as plurality of Cu1+ ions, a degradable phase including B2O3, P2O5 and K2O and a durable phase including SiO2. Other embodiments include glasses having a plurality of Cu1+ ions disposed on the surface of the glass and in the glass network and/or the glass matrix. The article may also include a polymer. The glasses and articles disclosed herein exhibit a 2 log reduction or greater in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomomas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing conditions and under Modified JIS Z 2801 for Bacteria testing conditions.

Abstract: Embodiments of the present invention pertain to antimicrobial glass compositions, glasses and articles. The articles include a glass, which may include a glass phase and a cuprite phase. In other embodiments, the glasses include as plurality of Cu1+ ions, a degradable phase including B2O3, P2O5 and K2O and a durable phase including SiO2. Other embodiments include glasses having a plurality of Cu1+ ions disposed on the surface of the glass and in the glass network and/or the glass matrix. The article may also include a polymer. The glasses and articles disclosed herein exhibit a 2 log reduction or greater in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing conditions and under Modified JIS Z 2801 for Bacteria testing conditions.

Abstract: Embodiments of the present invention pertain to antimicrobial glass compositions, glasses and articles. The articles include a glass, which may include a glass phase and a cuprite phase. In other embodiments, the glasses include as plurality of Cu1+ ions, a degradable phase including B2O3, P2O5 and K2O and a durable phase including SiO2. Other embodiments include glasses having a plurality of Cu1+ ions disposed on the surface of the glass and in the glass network and/or the glass matrix. The article may also include a polymer. The glasses and articles disclosed herein exhibit a 2 log reduction or greater in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing conditions and under Modified JIS Z 2801 for Bacteria testing conditions.

Abstract: A cosmetic product for hair dyeing or hair bleaching comprising a first agent containing an alkali agent and a second agent containing hydrogen peroxide, wherein viscosity of any one of the first agent and the second agent is 100 mPa·s or less, and viscosity of the other agent is 1000 mPa·s or more, the cosmetic product comprising components (A) to (D) in a mixture of the first agent and the second agent, wherein the mass ratio of [(B)+(C)]/(A) in the mixture is 2 or more and 11 or less: (A) a polymer containing a diallyl quaternary ammonium salt as a constitutional unit and having a charge density of 2.

Abstract: A topical composition comprising a non-denatured, broken-up and dried Porphyridium biomass that is not further processed and a pharmaceutically or cosmetically acceptable carrier useful for cosmetic treatments is described.

Abstract: The invention provides oral liquid midodrine formulation and uses thereof.

Abstract: A method for filling multiple colors of liquid color cosmetic materials, comprises the steps of: separating a sponge, into a plurality of sponge pieces by dividing the sponge; forming a coating film on the outer lateral side, or on the outer lateral side and on the lower surface of each of a plurality of the sponge pieces; impregnating different liquid color cosmetic materials into each of the sponge pieces having a coating film formed thereon; and fitting the angles of each of the sponge pieces, and coupling the sponge pieces. Liquid cosmetic materials having different colors are not mixed in one container without comprising a separate partition film, and a boundary line is clearly distinguished.

Abstract: The present invention relates to a composite preparation with various dosage forms comprising mosapride and rabeprazole. The composite preparation prepared according to the present invention allows rapid release of a drug without deteriorating its release by an interaction between mosapride and rabeprazole, thus exhibiting an improved drug release rate and bioavailability, while having excellent product stability and being capable of significantly lowering the amount of the excipient. Accordingly, the composite preparation of the present invention can improve patients' drug compliance due to the size of its dosage form.

Abstract: Provided herein are nitrite salts of 1,1-dimethylbiguanide; and isotopic variants thereof; and pharmaceutically acceptable hydrates and solvates thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of diseases associated with and/or caused by an abnormal blood glucose level. Further provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a cardiovascular disease.

Abstract: A package for storing or containing at least one ethylene response manipulation agent such as 1-methylcyclopropene is disclosed. The package can have multiple film layers, but preferably the outer layer comprises a polymer at least partially soluble when contacted with an aqueous media, and the inner layer comprising an ethylene response manipulation agent permeable film structure. Aerosols comprising the ethylene response manipulation agents are also disclosed.

Abstract: A method of fabrication produces one or more functional microparticles using a parallel pore working piece. In one embodiment, the method forms a particle that includes a segment for the oxidation of a biofuel (such as glucose) and the reduction of oxygen. The particle may be synthesized in a structure with defined and parallel, uniform, thin pores that completely penetrate the structure. Further, the functional microparticle may be configured to reside in a human or animal body or cell such that it may be self-contained fuel cell having an anode, a cathode, a separator membrane, and a magnetic component. In other embodiments, the functional microparticles may deliver energy or therapeutic materials in the body.

Abstract: The present disclosure relates to a method for manufacturing a device for herbal medicine in which the airborne release of medicinal ingredients can be controlled, which comprises: separating two or more medicinal herbal ingredients prescribed or prepared according to pharmacological effects on the basis of the weight ratio of each medicinal ingredient to total weight of the medicinal ingredients; grinding the medicinal ingredients separated on the basis of weight ratio, wherein fine particles are ground to different sizes according to the setting of release duration; preparing herbal medicine by mixing the ground medicinal ingredients together, and then mixing the ingredients with a binding agent; and adhering the herbal medicine to a base sheet.

Abstract: The present patent application relates to a novel coating system, wherein the coating comprises Carnauba wax and at least one polysorbate. Furthermore it relates to compositions coated with such a coating system and the use of such compositions in the production of tablets.

Abstract: This invention relates to crystalline salts of naloxone and of naltrexone and their use as opioid antagonists. The crystalline salts of the invention include naloxone saccharinate, naltrexone succinate and a methanol solvate of naltrexone succinate. A drug-in-adhesive transdermal patch containing the opioid analgesic fentanyl or an analog thereof and a crystalline salts of naloxone or naltrexone is disclosed. Also disclosed is a method of treating pain, such as acute, chronic or intermittent pain, by applying a drug-in-adhesive transdermal patch of the invention to the skin of a patient in need thereof.

Abstract: A method of preventing protein glycation using a supplement may comprise: administering a supplement comprising lysine and zinc; monitoring a concentration of glucose before and after the supplement is administered in a bio-sample; and determining a change in a dose of the supplement based on the concentration of glucose found in the bio-sample.

Abstract: A hydrogel delivery composition, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent.

Abstract: The present disclosure relates to cosmetic agents, which in addition to a deodorant agent contain a combination of special aromatic alcohols and certain menthyl compounds. These agents have a long-lasting deodorizing effect. The present disclosure also relates to a cosmetic product that includes the cosmetic agent as contemplated herein, as well as at least one propellant. The present disclosure also relates to the use of the agent as contemplated herein to treat body odor, as well as the use of a combination of aromatic alcohol and menthyl compounds to improve the odor-inhibiting effect of cosmetic agents over a period of from about 24 to about 48 hours.

Abstract: Disclosed is a cosmetic product comprising a metal can which comprises a metal container (A) which has a rotary thread (A?) and contains a cosmetic preparation as well as a lid (D) having a thread (D?) and being of the same metal as the container. The lid can be screwed onto/unscrewed from the container by means of threads (D?) and (A?) via rotational movement. The cosmetic preparation comprises an emulsion of one or more hydrophilic phases and one or more lipophilic phases. The one or more lipophilic phases comprise at least one lipid having a spreading coefficient at 25° C. of no more than 700 mm2/10 minutes, at least one lipid having a dropping point of >30° C., and at least one monovalent and/or polyvalent alcohol in a total amount of at least 3 wt. %.